» Articles » PMID: 9819361

A 6-basepair Insert in the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1 Confers Resistance to Multiple Nucleoside Inhibitors

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1998 Nov 20
PMID 9819361
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

While many point mutations in the HIV-1 reverse transcriptase (RT) confer resistance to antiretroviral drugs, inserts or deletions in this gene have not been previously characterized. In this report, 14 RT inhibitor-treated patients were found to have HIV-1 strains possessing a 6-basepair insert between codons 69 and 70 of the RT gene. Known drug resistance mutations were also observed in these strains, with T215Y appearing in all strains. Genotypic analysis indicated that the inserts had substantial nucleotide variability that resulted in relatively restricted sets of amino acid sequences. Linkage of patients' treatment histories with longitudinal sequencing data showed that insert strains appeared during drug regimens containing ddI or ddC, with prior or concurrent AZT treatment. Drug susceptibility tests of recombinant patient isolates showed reduced susceptibility to nearly all nucleoside RT inhibitors. Site- directed mutagenesis studies confirmed the role of the inserts alone in conferring reduced susceptibility to most RT inhibitors. The addition of AZT-associated drug resistance mutations further increased the range and magnitude of resistance. These results establish that inserts, like point mutations, are selected in vivo during antiretroviral therapy and provide resistance to multiple nucleoside analogs.

Citing Articles

The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter.

Apetroaei M, Velescu B, Nedea M, Dinu-Pirvu C, Draganescu D, Faca A Biomedicines. 2024; 12(4).

PMID: 38672269 PMC: 11048092. DOI: 10.3390/biomedicines12040915.


.

Bangoura N, Diouara A, Cisse M, Ndiaye H, Mboup S, Ayouba A Afr J Lab Med. 2024; 4(1):168.

PMID: 38440313 PMC: 10911652. DOI: 10.4102/ajlm.v4i1.168.


Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies.

Singh A, Das K Viruses. 2022; 14(5).

PMID: 35632767 PMC: 9148108. DOI: 10.3390/v14051027.


HIV-1 molecular epidemiology and drug resistance-associated mutations among treatment-naïve blood donors in China.

Zhao J, Lv X, Chang L, Ji H, Harris B, Zhang L Sci Rep. 2020; 10(1):7571.

PMID: 32371875 PMC: 7200736. DOI: 10.1038/s41598-020-64463-w.


Measurement error and variant-calling in deep Illumina sequencing of HIV.

Howison M, Coetzer M, Kantor R Bioinformatics. 2018; 35(12):2029-2035.

PMID: 30407489 PMC: 7963075. DOI: 10.1093/bioinformatics/bty919.


References
1.
Larder B, Darby G, Richman D . HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989; 243(4899):1731-4. DOI: 10.1126/science.2467383. View

2.
CARPENTER C, Fischl M, Hammer S, Hirsch M, Jacobsen D, Katzenstein D . Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998; 280(1):78-86. DOI: 10.1001/jama.280.1.78. View

3.
Bebenek K, Roberts J, Kunkel T . The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J Biol Chem. 1992; 267(6):3589-96. View

4.
Kellam P, Boucher C, Larder B . Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A. 1992; 89(5):1934-8. PMC: 48568. DOI: 10.1073/pnas.89.5.1934. View

5.
Fitzgibbon J, Howell R, Haberzettl C, Sperber S, Gocke D, DUBIN D . Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine. Antimicrob Agents Chemother. 1992; 36(1):153-7. PMC: 189244. DOI: 10.1128/AAC.36.1.153. View